Updates

Medica

November 2020

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

The teleradiology company has experienced all manner of push and pull in recent months. Latest H1 performance saw sales decreasing 23% to £17m. However, the company still generated a positive EBIT of £2m and eps of 1.3p and has maintained a strong net cash position of £8m, which has doubled from £4m at the end of FY19.Interims show Medica revising its divisional reporting structure into NightHawk and Elective (inclusive of routine, plain film and other). The H1 gross margin declined 50bps (on revenue mix and some updated pricing) to 47.1%.NightHawk’s reporting activity initially fell to c.60% of pre-COVID levels before recovering to pre-pandemic levels. Elective has, however, only recovered to 45 ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Pressure Technologies

Equals Group - Sales pivot to B2B - now 66% sales

Medica - Bid at 212p (May 2023)

Medica - Moves into US$1bn US clinical trials market (May 2021)

Medica Group (August 2020)

Medica (September 2018)

Medica - Radiology recruitment jumps in Q2 (May 2018)

Medica (February 2018)

Medica (November 2017)

Medica - Sets up advanced practitioner radiography network alongside radiologist one (May 2017)

Medica - Hot telehealth new issue (April 2017)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X